Search research articles
Contact Us
Filters
Showing results (161-170 of 249) with videos related to
Page
of 25
Sort By:
Cancer Research
|
May 17, 2011
HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer
Euan A Stronach, Albandri Alfraidi, Nona Rama, et al.
American Journal of Cancer Research
|
November 9, 2016
Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines
Marta Llauradó Fernández, Gabriel E DiMattia, Amy Dawson, et al.
Translational Oncology
|
August 27, 2024
Neratinib plus dasatinib is highly synergistic in HER2-positive breast cancer in vitro and in vivo
Neil T Conlon, Sandra Roche, Amira F Mahdi, et al.
Journal of Cancer Research and Clinical Oncology
|
December 8, 2011
Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes
Li-E Wang, Hongxia Ma, Katherine S Hale, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 21, 2012
Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement
S Guiu, S Michiels, F André, et al.
Cancer
|
April 8, 2011
Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer
Siqing Fu, Wei Hu, Revathy Iyer, et al.
Cancer Research
|
May 14, 2009
Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer
Todd W Miller, Marianela Pérez-Torres, Archana Narasanna, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 12, 2009
Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer
Ana M Gonzalez-Angulo, Katherine Stemke-Hale, Shana L Palla, et al.
Cancer Medicine
|
November 23, 2019
Similar overall survival with reduced vs. standard dose bevacizumab monotherapy in progressive glioblastoma
Jack Patrick Gleeson, Fergus Keane, Niamh M Keegan, et al.
BMC Cancer
|
January 17, 2024
Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study)
Gavin P Dowling, Sinead Toomey, Philip Bredin, et al.
Page
of 25
Search research articles
Search
Showing results (161-170 of 249) with videos related to
Sort By:
Page
of 25
Cancer Research
|
May 17, 2011
HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer
Euan A Stronach, Albandri Alfraidi, Nona Rama, et al.
American Journal of Cancer Research
|
November 9, 2016
Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines
Marta Llauradó Fernández, Gabriel E DiMattia, Amy Dawson, et al.
Translational Oncology
|
August 27, 2024
Neratinib plus dasatinib is highly synergistic in HER2-positive breast cancer in vitro and in vivo
Neil T Conlon, Sandra Roche, Amira F Mahdi, et al.
Journal of Cancer Research and Clinical Oncology
|
December 8, 2011
Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes
Li-E Wang, Hongxia Ma, Katherine S Hale, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 21, 2012
Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement
S Guiu, S Michiels, F André, et al.
Cancer
|
April 8, 2011
Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer
Siqing Fu, Wei Hu, Revathy Iyer, et al.
Cancer Research
|
May 14, 2009
Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer
Todd W Miller, Marianela Pérez-Torres, Archana Narasanna, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 12, 2009
Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer
Ana M Gonzalez-Angulo, Katherine Stemke-Hale, Shana L Palla, et al.
Cancer Medicine
|
November 23, 2019
Similar overall survival with reduced vs. standard dose bevacizumab monotherapy in progressive glioblastoma
Jack Patrick Gleeson, Fergus Keane, Niamh M Keegan, et al.
BMC Cancer
|
January 17, 2024
Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study)
Gavin P Dowling, Sinead Toomey, Philip Bredin, et al.
Page
of 25